AU2011310096B2 - Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E - Google Patents

Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E Download PDF

Info

Publication number
AU2011310096B2
AU2011310096B2 AU2011310096A AU2011310096A AU2011310096B2 AU 2011310096 B2 AU2011310096 B2 AU 2011310096B2 AU 2011310096 A AU2011310096 A AU 2011310096A AU 2011310096 A AU2011310096 A AU 2011310096A AU 2011310096 B2 AU2011310096 B2 AU 2011310096B2
Authority
AU
Australia
Prior art keywords
antibody
cancer
braf
sample
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011310096A
Other languages
English (en)
Other versions
AU2011310096A1 (en
Inventor
David Capper
Andreas Von Deimling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Universitaet Heidelberg
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Universitaet Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ, Universitaet Heidelberg filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of AU2011310096A1 publication Critical patent/AU2011310096A1/en
Assigned to DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG reassignment DEUTSCHES KREBSFORSCHUNGSZENTRUM Amend patent request/document other than specification (104) Assignors: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERISTAT HEIDELBERG
Application granted granted Critical
Publication of AU2011310096B2 publication Critical patent/AU2011310096B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G01N33/57505—
    • G01N33/5751—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2011310096A 2010-09-30 2011-09-30 Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E Active AU2011310096B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38815810P 2010-09-30 2010-09-30
US61/388,158 2010-09-30
US201161503950P 2011-07-01 2011-07-01
US61/503,950 2011-07-01
PCT/EP2011/067092 WO2012042009A1 (en) 2010-09-30 2011-09-30 Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e

Publications (2)

Publication Number Publication Date
AU2011310096A1 AU2011310096A1 (en) 2013-04-18
AU2011310096B2 true AU2011310096B2 (en) 2014-11-06

Family

ID=44789447

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011310096A Active AU2011310096B2 (en) 2010-09-30 2011-09-30 Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E

Country Status (9)

Country Link
US (1) US9297812B2 (cg-RX-API-DMAC7.html)
EP (1) EP2622348B1 (cg-RX-API-DMAC7.html)
JP (1) JP5893037B2 (cg-RX-API-DMAC7.html)
CN (1) CN103403550B (cg-RX-API-DMAC7.html)
AU (1) AU2011310096B2 (cg-RX-API-DMAC7.html)
CA (1) CA2813098C (cg-RX-API-DMAC7.html)
DK (1) DK2622348T3 (cg-RX-API-DMAC7.html)
ES (1) ES2554678T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012042009A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172744B (zh) * 2012-09-28 2016-01-13 武汉纽斯特生物技术有限公司 特异性识别B-Raf突变蛋白的单克隆抗体、制备方法及其应用
JP6485854B2 (ja) * 2014-09-24 2019-03-20 国立研究開発法人国立循環器病研究センター 抗変異型プロテインｓ抗体、該抗体を含む診断用組成物、変異型ヒトプロテインｓの検出方法および該抗体を含むキット
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2019004703A1 (ko) * 2017-06-29 2019-01-03 한국과학기술원 신경절 교세포종 및 이와 관련된 질환의 진단, 예방, 또는 치료용 조성물
CN110183535A (zh) * 2018-12-17 2019-08-30 南京基诺米医疗科技有限公司 鼠抗人braf v600e突变蛋白单克隆抗体制备及其免疫组化用途
CN111285935B (zh) * 2020-05-13 2020-09-11 方达医药技术(上海)有限公司 特异性检测braf基因突变的抗体及其在制备癌症检测试剂盒中的用途
AU2021378815A1 (en) * 2020-11-16 2023-06-29 Agilent Technologies, Inc. Chimeric anti-human braf v600e antibodies and methods for making and using them
JPWO2024090265A1 (cg-RX-API-DMAC7.html) * 2022-10-28 2024-05-02

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047542A1 (en) * 2003-10-16 2005-05-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
WO2007002811A2 (en) * 2005-06-29 2007-01-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating melanoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6735531B2 (en) * 1996-10-07 2004-05-11 Lab Vision Corporation Method and apparatus for automatic tissue staining
EP3399520B1 (en) * 2007-09-11 2022-01-05 University of Massachusetts Insulin-like growth factor binding protein 7 for use in treatment of cancer
JP2009077712A (ja) 2007-09-11 2009-04-16 F Hoffmann La Roche Ag Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047542A1 (en) * 2003-10-16 2005-05-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
WO2007002811A2 (en) * 2005-06-29 2007-01-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating melanoma

Also Published As

Publication number Publication date
US9297812B2 (en) 2016-03-29
JP5893037B2 (ja) 2016-03-23
CN103403550B (zh) 2015-08-19
US20130266962A1 (en) 2013-10-10
CN103403550A (zh) 2013-11-20
DK2622348T3 (en) 2015-12-14
WO2012042009A1 (en) 2012-04-05
AU2011310096A1 (en) 2013-04-18
CA2813098A1 (en) 2012-04-05
ES2554678T3 (es) 2015-12-22
JP2013543117A (ja) 2013-11-28
EP2622348A1 (en) 2013-08-07
CA2813098C (en) 2019-10-08
EP2622348B1 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
AU2011310096B2 (en) Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E
EP2438442B1 (en) Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
AU2010311540B2 (en) PODXL protein in colorectal cancer
US9618512B2 (en) Biomarker for breast cancer
EP2554993A1 (en) Marker for diagnosing effect of anticancer agent
EP2288721B1 (en) Treatment prediction involving hmgcr protein
JP4560314B2 (ja) 中性アミノ酸トランスポーターによる癌の検出法、及びそのためのキット
WO2025026204A1 (en) Antibodies against ror1 and uses thereof
JP6195716B2 (ja) 抗癌剤耐性診断マーカー
CA2642419A1 (en) Gpr30 estrogen receptor in breast cancers
US20130143231A1 (en) MST1/STK4 PHOSPHO-THREONINE 120 (pMST-T120) ANTIBODY

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)